Monthly aflibercept associated with less progression of retinal nonperfusion
Click Here to Manage Email Alerts
WAIKOLOA, Hawaii — Treatment with monthly aflibercept resulted in less progression of retinal nonperfusion compared with quarterly aflibercept in patients with proliferative diabetic retinopathy, according to a speaker here.
“Overall, what is clear is that nonperfusion progresses despite an apparent improvement in diabetic retinopathy scores in these patients,” SriniVas Sadda, MD, said at Retina 2022 on behalf of the investigators of the RECOVERY trial.
RECOVERY trial researchers investigated the effect of aflibercept 2 mg on retinal nonperfusion in patients with proliferative diabetic retinopathy without diabetic macular edema. Adults with type 1 or type 2 diabetes and treatment-naive proliferative diabetic retinopathy were included. Patients with traction retinal detachment threatening the macula, vitreous hemorrhage preventing retinal imaging and uncontrolled blood pressure were excluded.
Patients were randomly assigned to receive monthly aflibercept injections or quarterly aflibercept injections. After 1 year, the arms crossed over to receive injections on the other arm’s schedule.
From baseline through year 1, patients in the monthly arm experienced a 0.05% decrease in retinal nonperfusion area. From year 1 to year 2, these patients experienced an increase of 53% in retinal nonperfusion area, with an overall increase of 46% (P < .0001).
Patients in the quarterly arm experienced a 29% increase from baseline through year 1 and a 59% increase from year 1 to year 2, with an overall increase of 103% (P < .0001).
“At the primary 1-year endpoint, in eyes with PDR without DME, monthly aflibercept 2 mg was associated with less progression of retinal nonperfusion compared with quarterly treatment,” Sadda wrote in the presentation.
Collapse
Sadda S. Anti-VEGF therapy and retinal non-perfusion in diabetic retinopathy: Lessons from the RECOVERY study. Presented at: Retina 2022; Jan. 15-21, 2022; Waikoloa, Hawaii.
Read more about
Click Here to Manage Email Alerts